Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $9,425 | 3 | 72.4% |
| Unspecified | $3,600 | 2 | 27.6% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $9,425 | 3 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $3,600 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,600 | 2 | E.R. Squibb & Sons, L.L.C. ($3,600) |
| 2020 | $2,750 | 1 | Eisai Inc. ($2,750) |
| 2018 | $6,675 | 2 | Eisai Inc. ($6,675) |
All Payment Transactions
5 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/07/2024 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $1,800.00 | Research |
| Study: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia | ||||||
| 07/01/2024 | E.R. Squibb & Sons, L.L.C. | — | — | Cash or cash equivalent | $1,800.00 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease | ||||||
| 10/05/2020 | Eisai Inc. | Dayvigo (Drug) | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| Category: Neurology | ||||||
| 03/09/2018 | Eisai Inc. | — | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| 02/22/2018 | Eisai Inc. | — | Consulting Fee | Cash or cash equivalent | $4,425.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease | E.R. Squibb & Sons, L.L.C. | $1,800 | 1 |
| A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia | E.R. Squibb & Sons, L.L.C. | $1,800 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 259 | 588 | $179,201 | $40,705 |
| 2022 | 10 | 263 | 776 | $150,220 | $36,048 |
| 2021 | 10 | 308 | 907 | $184,369 | $43,082 |
| 2020 | 9 | 325 | 742 | $171,151 | $40,359 |
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 44 | 218 | $56,293 | $13,664 | 24.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 57 | 101 | $31,675 | $6,505 | 20.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 21 | 60 | $23,400 | $5,613 | 24.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 35 | 49 | $21,686 | $4,199 | 19.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 35 | 41 | $15,408 | $3,740 | 24.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 21 | 32 | $14,759 | $3,240 | 22.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 19 | 60 | $7,680 | $1,996 | 26.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 12 | 12 | $5,370 | $1,115 | 20.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 15 | 15 | $2,930 | $632.38 | 21.6% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 52 | 477 | $58,739 | $14,770 | 25.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 56 | 95 | $28,013 | $6,069 | 21.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 38 | 66 | $15,225 | $3,704 | 24.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 16 | 16 | $10,151 | $2,539 | 25.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 14 | 25 | $8,397 | $2,042 | 24.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 21 | 24 | $8,232 | $2,016 | 24.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 15 | 15 | $8,151 | $1,894 | 23.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 20 | 20 | $4,580 | $1,160 | 25.3% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 11 | 13 | $4,212 | $981.64 | 23.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 20 | 25 | $4,520 | $873.64 | 19.3% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 57 | 573 | $76,990 | $17,299 | 22.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 57 | 108 | $28,696 | $7,286 | 25.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 27 | 28 | $18,606 | $4,495 | 24.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 40 | 61 | $14,183 | $3,457 | 24.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 25 | 25 | $13,809 | $3,141 | 22.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 30 | 30 | $10,755 | $2,560 | 23.8% |
About Larry Tune
Larry Tune is a Psychiatry healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1083780043.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Larry Tune has received a total of $13,025 in payments from pharmaceutical and medical device companies, with $3,600 received in 2024. These payments were reported across 5 transactions from 2 companies. The most common payment nature is "Consulting Fee" ($9,425).
As a Medicare-enrolled provider, Tune has provided services to 1,155 Medicare beneficiaries, totaling 3,013 services with total Medicare billing of $160,195. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Practice Information
- Specialty Psychiatry
- Location Atlanta, GA
- Active Since 11/28/2006
- Last Updated 07/08/2007
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1083780043
Products in Payments
- Dayvigo (Drug) $2,750
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Atlanta
Dr. David Purselle, Md, Ms, MD, MS
Psychiatry — Payments: $276,165
Dr. Michael Burke, Md, MD
Psychiatry — Payments: $266,079
Dr. Kerry Ressler, Md,Phd, MD,PHD
Psychiatry — Payments: $180,346
Dr. Alyssa Rosen, M.d, M.D
Psychiatry — Payments: $128,521
Boadie Dunlop, Md, MD
Psychiatry — Payments: $72,811
Patricio Riva Posse, M.d, M.D
Psychiatry — Payments: $66,726